| Literature DB >> 35920542 |
Daniele Porto Barros1,2, Priscilla Sete de Carvalho Onofre1,2, Fernando Luiz Affonso Fonseca3, Paulo César Pires Rosa4, Mavilde da Luz Gonçalves Pedreira1, Maria Angélica Sorgini Peterlini1.
Abstract
OBJECTIVE: to verify the stability of vancomycin hydrochloride in antimicrobial seal solutions with and without association of heparin sodium according to temperature and association time.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35920542 PMCID: PMC9342908 DOI: 10.1590/1518-8345.5869.3620
Source DB: PubMed Journal: Rev Lat Am Enfermagem ISSN: 0104-1169
Concentration and hydrogenionic potential of vancomycin hydrochloride solutions (n=6) and of the vancomycin hydrochloride-heparin sodium association (n=6) according to temperature and time. São Paulo, SP, Brazil, 2018
| Temperature | Type of solution | Moment | Concentration (%) Mean ± SD (Min-Max) | Concentration (mg/mL) Mean ± SD (Min-Max) | Hydrogenioninc potential Mean ± SD (Min-Max) |
|---|---|---|---|---|---|
| 22ºC | Vancomycin hydrochloride solution | T0 | 101.93 ± 1.66* | 5.10 ± 0.08* | 3.76 ± 0.05* |
| (100.75-104.33) | (5.04-5.22) | (3.73-3.82) | |||
| T3 | 101.45 ± 1.46 | 5.07 ± 0.07 | 3.73 ± 0.01* | ||
| (99.54-103.58) | (4.98-5.18) | (3.73-3.74) | |||
| T8 | 100.31 ± 0.87† | 5.02 ± 0.04† | 3.74 ± 0.01* | ||
| (99.39-101.39) | (4.97-5.07) | (3.73-3.75) | |||
| T24 | 102.50 ± 1.46* | 5.12 ± 0.07* | 3.59 ± 0.03† | ||
| (100.52-104.44) | (5.03-5.22) | (3.56-3.62) | |||
| p | <0.05 | <0.05 | <0.05 | ||
| Vancomycin hydrochloride and heparin sodium solution | T0 | 101.73 ± 3.81* | 5.09 ± 0.19* | 3.63 ± 0.03† | |
| (95.50-106.64) | (4.78-5.33) | (3.60-3.65) | |||
| T3 | 99.01 ± 1.56† | 4.95 ± 0.08† | 3.59 ± 0.02† | ||
| (97.49-101.24) | (4.87-5.06) | (3.58-3.61) | |||
| T8 | 97.38 ± 1.20† | 4.87 ± 0.06† | 3.64 ± 0.04† | ||
| (95.60-98.80) | (4.78-4.94) | (3.61-3.69) | |||
| T24 | 96.34 ± 1.70† | 4.82 ± 0.08† | 4.00 ± 0.02* | ||
| (94.36-99.44) | (4.72-4.97) | (3.99-4.02) | |||
| p | <0.05 | 0.05 | <0.05 | ||
| 37ºC | Vancomycin hydrochloride solution | T0 | 97.79 ± 0.69† | 4.89 ± 0.03† | 3.73 ± 0.02* |
| (96.99-98.97) | (4.85-4.95) | (3.71-3.74) | |||
| T3 | 101.96 ± 1.13* | 5.10 ± 0.06* | 3.69 ± 0.02† | ||
| (100.25-102.92) | (5.01-5.15) | (3.68-3.71) | |||
| T8 | 100.73 ± 1.69* | 5.04 ± 0.08* | 3.67 ± 0.01† | ||
| (98.77-102.58) | (4.94-5.13) | (3.66-3.68) | |||
| T24 | 98.35 ± 2.80† | 4.92 ± 0.14† | 3.68 ± 0.02† | ||
| (95.41-101.83) | (4.77-5.09) | (3.66-3.69) | |||
| p | <0.05 | <0.05 | 0.05 | ||
| Vancomycin hydrochloride and heparin sodium solution | T0 | 94.91 ± 1.76† | 4.75 ± 0.09† | 3.80 ± 0.02 | |
| (92.68-96.80) | (4.63-4.84) | (3.78-3.82) | |||
| T3 | 95.12 ± 1.29† | 4.76 ± 0.06† | 3.75 ± 0.07 | ||
| (93.19-96.80) | (4.66-4.84) | (3.68-3.82) | |||
| T8 | 95.05 ± 3.15† | 4.75 ± 0.16† (4.54-4.97) | 3.75 ± 0.04 | ||
| (90.84-99.43) | (3.72-3.79) | ||||
| T24 | 96.94 ± 1.23* | 4.85 ± 0.06* | 3.78 ± 0.01 | ||
| (94.94-98.42) | (4.75-4.92) | (3.78-3.79) | |||
| p | 0.001 | 0.001 | 0.389 |
*Analysis of variance (ANOVA); †Multiple comparisons Bonferroni correction; (*) and (†) present different means between the evaluation moments for each. The results are expressed through mean ± standard deviation
Figure 1Mean values of concentration and hydrogenionic potential of the vancomycin hydrochloride solutions and of those of the vancomycin hydrochloride-heparin sodium association, according use time and exposure temperature. São Paulo, SP, Brazil, 2018
Figure 2Concentration and hydrogenionic potential of the vancomycin hydrochloride solutions and of those containing the vancomycin hydrochloride-heparin sodium association, according to the influence of time and temperature on multiple paired comparisons (a posteriori Bonferroni test). São Paulo, SP, Brazil, 2018
Figure 3Vancomycin hydrochloride and heparin sodium solution at the different moment: initial; and after three, eight and 24 hours of use of the solutions at a temperature of 22°C; and with formation of a cloudy solution at three hours of preparation. São Paulo, SP, Brazil, 2018